Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist injection for type 2 diabetes. Several alternatives exist — other GLP-1 RAs like Ozempic, the dual-agonist Mounjaro, the oral option Rybelsus, and non-GLP-1 classes such as SGLT2 inhibitors and DPP-4 inhibitors. The best choice depends on glucose goals, weight aims, cardiovascular risk, cost, and injection preference.
Why People Look for Trulicity Alternatives
- Inadequate A1C control at maximum 4.5 mg weekly dose
- Persistent or worsening GI side effects
- Desire for greater weight loss
- Cost or insurance coverage changes
- Preference for oral over injectable
- Stronger cardiovascular or kidney protection desired
- Supply shortages or pharmacy access issues
- Adverse reaction to dulaglutide specifically
Other GLP-1 Receptor Agonists
| Drug | Active Ingredient | Schedule | A1C Reduction | Weight Loss |
|---|---|---|---|---|
| Trulicity | Dulaglutide | Weekly injection | ~1.0–1.5% | ~2–4 kg |
| Ozempic | Semaglutide | Weekly injection | ~1.5–1.8% | ~4–6 kg |
| Victoza | Liraglutide 1.8 mg | Daily injection | ~1.0–1.5% | ~2–3 kg |
| Bydureon BCise | Exenatide ER | Weekly injection | ~1.0–1.5% | ~2–3 kg |
| Rybelsus | Oral semaglutide | Daily tablet | ~1.0–1.5% | ~2–4 kg |
| Saxenda | Liraglutide 3.0 mg | Daily injection (weight loss) | — | ~5–8 kg |
| Wegovy | Semaglutide 2.4 mg | Weekly injection (weight loss) | — | ~12–15 kg |
Ozempic (Semaglutide)
The most direct head-to-head alternative to Trulicity. Same once-weekly injection schedule. In SUSTAIN-7, Ozempic 1.0 mg produced 1.8 percent A1C reduction versus 1.4 percent with Trulicity 1.5 mg, and 6.5 kg weight loss versus 3.0 kg. Side-effect profile is similar. For a side-by-side, see our is Trulicity the same as Ozempic guide.
Victoza (Liraglutide)
Daily injection. Same molecule as Saxenda (used for weight loss). Approved for adults and adolescents 10 years and older with type 2 diabetes. Cardiovascular outcomes data from LEADER trial. Less convenient than weekly drugs but useful for patients who do better with daily routines or have specific insurance coverage. See Victoza for diabetes.
Bydureon BCise (Exenatide ER)
Weekly extended-release injection. Older mechanism with somewhat less weight loss and A1C reduction than Ozempic. Higher rate of injection site nodules. Generally less prescribed than Trulicity or Ozempic now, but still an option for some patients.
Rybelsus (Oral Semaglutide)
The only oral GLP-1 receptor agonist. Daily 7 or 14 mg tablet taken on an empty stomach with no more than 4 oz of water, at least 30 minutes before food, drink, or other medications. Useful for patients who prefer to avoid injections. A1C reduction is modestly lower than injectable Ozempic at maximum dose. See our Rybelsus semaglutide tablets coverage.
Mounjaro (Tirzepatide) — Dual GIP/GLP-1 Agonist
Mounjaro is technically not a pure GLP-1 RA — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. In SURPASS-2, Mounjaro produced 2.3 percent A1C reduction and 11 kg weight loss at the 15 mg dose, versus 1.9 percent and 7 kg with semaglutide 1.0 mg.
- Once-weekly injection
- Doses: 2.5 (starter), 5, 7.5, 10, 12.5, 15 mg
- 4-week escalation between doses
- Same boxed warning and side-effect class as GLP-1 RAs
- Higher cost; often requires prior authorization
- The weight-loss version is branded Zepbound
Non-GLP-1 Alternatives
SGLT2 Inhibitors
| Drug | Brand | Strongest Benefit |
|---|---|---|
| Empagliflozin | Jardiance | CV mortality reduction (EMPA-REG) |
| Dapagliflozin | Farxiga | Heart failure and CKD outcomes |
| Canagliflozin | Invokana | Renal outcomes (CREDENCE) |
| Ertugliflozin | Steglatro | A1C reduction |
Oral, once-daily. A1C reduction 0.7 to 1.0 percent. Weight loss 2 to 3 kg. Excellent for patients with cardiovascular disease, heart failure, or chronic kidney disease. Main side effects: genital yeast infections, UTIs, volume depletion, rare euglycemic DKA.
DPP-4 Inhibitors
- Sitagliptin (Januvia)
- Linagliptin (Tradjenta)
- Saxagliptin (Onglyza)
- Alogliptin (Nesina)
Oral, well-tolerated, weight-neutral. A1C reduction 0.5 to 0.8 percent — less potent than GLP-1 RAs but easier on the GI tract. Useful when tolerability matters more than maximum efficacy.
Sulfonylureas
Glipizide, glimepiride, glyburide. Inexpensive, potent (A1C 1.0 to 1.5 percent), but cause hypoglycemia and weight gain. Used when cost is a barrier or in addition to other agents.
Insulin
Long-acting basal insulins (glargine, degludec, detemir) are used when oral and non-insulin injectables fail to achieve glucose goals. Highly effective but require injections, glucose monitoring, and carry hypoglycemia risk.
Choosing the Right Alternative
| Goal | Best Trulicity Alternative |
|---|---|
| Maximum A1C reduction | Mounjaro > Ozempic > Trulicity |
| Maximum weight loss | Mounjaro/Zepbound > Ozempic/Wegovy > Saxenda |
| Avoid injections | Rybelsus (GLP-1) or SGLT2/DPP-4 |
| Heart failure | SGLT2 inhibitor (Jardiance, Farxiga) |
| Chronic kidney disease | SGLT2 inhibitor (Farxiga, Jardiance) |
| Reduced cost | Sulfonylurea or generic DPP-4 (when available) |
| GI intolerance | DPP-4 inhibitor or SGLT2 inhibitor |
| Established CV disease | GLP-1 RA or SGLT2 inhibitor with proven CV benefit |
Cost Comparison (US List Prices)
| Drug | Approximate Monthly Cost |
|---|---|
| Trulicity | ~$987 |
| Ozempic | ~$998 |
| Mounjaro | ~$1,070 |
| Rybelsus | ~$995 |
| Victoza | ~$700–900 |
| Bydureon | ~$800 |
| Jardiance | ~$600 |
| Farxiga | ~$600 |
| Generic sitagliptin | ~$200–400 |
| Sulfonylureas (generic) | ~$4–15 |
Insurance often dictates final out-of-pocket cost. Manufacturer savings cards and patient assistance programs may reduce monthly outlay substantially for eligible commercially insured patients.
Cardiovascular and Kidney Outcomes
| Drug | CV Outcomes Trial | Key Result |
|---|---|---|
| Trulicity | REWIND | 12% reduction MACE |
| Ozempic | SUSTAIN-6, SELECT | 26% reduction MACE; weight-loss CV benefit |
| Victoza | LEADER | 13% reduction MACE |
| Mounjaro | SURPASS-CVOT (pending) | Active study |
| Jardiance | EMPA-REG, EMPEROR | CV death, heart failure |
| Farxiga | DECLARE, DAPA-HF, DAPA-CKD | Heart failure, CKD progression |
How to Switch From Trulicity
- Discuss goals (glucose, weight, CV protection, cost) with your clinician
- Choose the new drug class and specific agent
- Final Trulicity injection — wait 7 days for the next dose
- Start the new drug at its starter dose
- Escalate per the new drug’s titration schedule
- Expect renewed GI side effects during titration of a new GLP-1 RA
- Recheck A1C in 3 months
- Continue lifestyle changes throughout the transition
Important Cautions
- Do not overlap two GLP-1 RAs in the same week
- All GLP-1 RAs and Mounjaro share the thyroid C-cell tumor boxed warning — avoid in MTC or MEN2
- SGLT2 inhibitors are not appropriate in low eGFR or recurrent UTIs
- Pancreatitis and gallbladder events are class effects
- Do not stop any diabetes medication abruptly without medical supervision
- Diet and exercise remain foundational — see our diet and nutrition hub
Related Resources
- See our Trulicity class guide for drug class context
- Compare whether Trulicity is a semaglutide
- Review treatment overview for all options
- Read A1C levels for treatment goals
The Bottom Line
The best Trulicity alternative depends on your goals. For more potency in glucose and weight, switch to Ozempic or Mounjaro. To avoid injections, consider Rybelsus or an SGLT2 inhibitor. For heart failure or chronic kidney disease, an SGLT2 inhibitor (Jardiance or Farxiga) may add specific benefit. For cost-constrained patients, a sulfonylurea or generic DPP-4 inhibitor may suffice. Work with your clinician to choose, switch safely, and monitor response. For broader context, see the ADA medication management overview.
